When we characterized the tumor-infiltrating lymphocytes, we found comparable numbers of CD3+CD8+ effector cells irrespective whether a tumor evolved in wild type or PI3Kδ−/− recipients (Figure 5C). The gene discussed is CD8A; the disease is neoplasm.